Pharmacology News

New data showed that 2% of patients receiving low- or moderate-intensity statin therapy had estimated severe hypercholesterolemia but received less aggressive therapy than those with maximum measured severe hypercholesterolemia.

HHS recently announced a plan supporting legislation that would allow it to negotiate Medicare Part B and Part D drug prices directly with pharmaceutical companies and then make those prices available to other purchasers.

In patients with HF with preserved ejection fraction, empagliflozin reduced risk for serious hospitalizations compared with placebo, according to new data from the EMPEROR-Preserved trial.

Patients who continued to use anticoagulant therapy beyond the initial 3 to 6 months of treatment for a first unprovoked venous thromboembolism were at “considerable” risk for major bleeding, researchers wrote.

HHS Secretary Xavier Becerra has announced a plan to lower prescription drug prices by “promoting negotiation, competition and innovation in the health care industry.”

Lowering BP through medication reduced risk for CV events across almost all age groups, suggesting age-related BP thresholds should be removed from guidelines, researchers reported at the European Society of Cardiology Congress.

The novel muscarinic M3 receptor antagonist DA8010 significantly reduced urine frequency and urgency episodes compared with placebo in adults with overactive bladder, according to recent findings.

A web application to help individuals self-prescribe statin therapy demonstrated 96% agreement with subsequent physician judgment, according to research published in the Journal of the American College of Cardiology.

Compared with placebo, dapagliflozin reduced risk for ventricular arrhythmias, cardiac arrest and sudden death, according to new data from the DAPA-HF trial.

Several medical organizations said they were vehemently “against the ordering, prescribing or dispensing of ivermectin to prevent or treat COVID-19” when it is not being used in a clinical trial.